Pharma BD Deal Intelligence
A $2.7B acquisition that paired UCB's chemistry with Celltech's biologics pipeline and delivered Cimzia (certolizumab pegol), a blockbuster still generating nearly €2B in annual sales two decades later. The deal funded a full pivot from chemicals conglomerate to pure biopharma, with Celltech's Slough site enduring as a core UCB immunology R&D hub.
Celltech's CDP870 became Cimzia — a ~$2B/year blockbuster that anchored UCB's transformation into a biopharma company for two decades
Full analysis, sources & comparables →UCB launched a friendly £1.53B (~$2.7B) cash offer for Celltech, citing CDP870 and the antibody platform as creating Europe's #2 biopharma.
Nature Biotechnology characterized the Celltech acquisition as sending mixed messages on the UK biotech sector - validation of asset value but loss of the…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Friendly offer £1.53B (~$2.7B); UK biotech; CDP870 lead asset; created Europe's #2 biopharma
Celltech's CDP870 became Cimzia — a ~$2B/year blockbuster that anchored UCB's transformation into a biopharma company for two decades
Assessment window: 15yr post-close.
Crohn's disease and rheumatoid arthritis are chronic, immune-mediated inflammatory conditions driven in part by tumor necrosis factor-alpha (TNF-alpha). Treatment shifted in the early 2000s from corticosteroids and immunomodulators toward injectable biologics that neutralize TNF-alpha, transforming patient outcomes but creating a heavily branded specialty market.
By 2004 the anti-TNF class was anchored by Johnson & Johnson/Centocor's Remicade (infliximab), Amgen/Wyeth's Enbrel (etanercept), and Abbott's newly launched Humira (adalimumab), which together would cross $10B in annual sales by mid-decade. Celltech's CDP870 (certolizumab pegol, later Cimzia) was a PEGylated Fab fragment differentiated by lack of an Fc region and a once-monthly subcutaneous dose, with Phase III readouts pending in Crohn's disease (launch targeted 2006) and rheumatoid arthritis (launch targeted 2007). Analysts modeled CDP870 peak sales near $740M by 2010. UCB's £1.53B (~$2.7B) friendly cash offer in May 2004 - the largest UK biotech takeover at the time - gave UCB full ownership of CDP870 plus Celltech's antibody engineering platform and US specialty sales infrastructure, while ending Celltech's existence as the UK's largest pure biotech. Cimzia was approved by the FDA in April 2008 and went on to become a multi-indication TNF franchise.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| UCB SA / Celltech Group plc (this deal) | 2004 | $2.7B | 92 |
| UCB SA / Schwarz Pharma AG | 2006 | $5.6B | 80 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Biogen Idec Inc. / Elan Corporation plc (Tysabri rights) | 2013 | $3.2B | 77 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
← Browse all deals · How we score deals
More: 2004 deals · Gastroenterology deals